Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis

BackgroundCFTR modulator therapies have positive clinical outcomes, yet chronic inflammation and bacterial infections persist in people with CF (pwCF). How elexacaftor–tezacaftor–ivacaftor (ETI) fails to improve innate immune signaling responsible for bacterial clearance and inflammation resolution...

Descrición completa

Detalles Bibliográficos

Principais autores:	Hazel Ozuna, Dinesh Bojja, Santiago Partida-Sanchez, Luanne Hall-Stoodley, Amal Amer, Rodney D. Britt, Shahid Sheikh, David A. Frank, Weiyuan Wang, Bum-Yong Kang, Irina Miralda, Samantha L. Durfey, Benjamin T. Kopp
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Assuntos:	cystic fibrosis inflammation proteomics modulators NF-κB
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1486784/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!